Our team of multi-disciplinary scientists and engineers have once again improved on the NuTec Slide. This was only made possible by building on past insights and proprietary know-how. The latest version of NuTec Slides show improved reproducibility and sample discernment, while being able to handle a wider range of sample intensities. The Gen 5 NuTec Slide will be used for commercial applications in the U.S.
Great article on our team’s efforts to detect cancer early and thereby improve healthcare outcomes, while reducing costs.
Want a PDF copy of the article? e-mail us at email@example.com
Our team submitted a research manuscript for peer-review describing the unique approach utilized by OpsisDx to categorize samples and patients. We included data from a clinical study as a means of validating the platform for clinical use.
A shortage of COVID-19 testing supplies is hampering people’s ability to perform timely RT-PCR testing. A key bottleneck is viral RNA extraction, which involves multiple steps, reagents and devices.
Our team is now investigating whether we can apply our PCRopsis technology and know-how to facilitate direct RT-PCR from nasal-pharyngeal and saliva samples by skipping the RNA extraction step.
Stay tuned for research updates on this promising approach in the battle against the pandemic.
Check-out our other PCRopsis products that allow you to perform PCR directly from clinical samples: PCRopsis.com
Entopsis recently signed licensing agreements with a CLIA-certified diagnostic laboratory to commercialize 4 oncology OpsisDx tests in the USA. This represents the first step in bringing OpsisDx to market.
The Entopsis team continues to prove-out the capabilities of OpsisDx for the early detection of other cancers, infectious diseases and mental illnesses. These efforts are aimed at establishing additional partnerships globally for a variety of medical conditions so that we can offer better health outcomes to all people.
Preliminary results are in from the on-going international clinical study exploring the ability of OpsisDx to accurately identify people with multiple diseases.
- OpsisDx distinguishes between people with cancer, hepatitis B viral and healthy controls
- OpsisDx accurately identifies patient’s cancer tissue of origin (lung, prostate, breast, liver or colorectal)
- Hepatitis B viral infection, often linked to increased likelihood for liver cancer, is observed as a distinct category from liver cancer patients
- OpsisDx detects more stage I cancers than liquid biopsies as performed by GRAIL
Can OpsisDx distinguish between similar molecules? Let’s say between different salts or isomers of carrageenan or phenol vs cresol?
YES … we observe distinct NuTec profiles for each molecule or mixture, even for molecules with similar structures.
This provides a framework for people to better grasp the inner workings of OpsisDx.
We are obsessed with efficiency and committed to manufacturing in the U.S. all critical OpsisDx components.
Our NuTec Slide manufacturing team incorporates a new robot to the manufacturing process. This addition, plus updates to current automated manufacturing processes, more than quadruples our manufacturing capabilities. These updates set the ground work for future scale-up efforts.
Our team of scientists have completed a re-design of the NuTec Slide based on our continued research into this new field. This latest version offers increased reproducibility and stability. The generation 4 NuTec Slide will be used in an international, multi-disease study.